Skip to main content
. 2022 May 6;10(5):1081. doi: 10.3390/biomedicines10051081

Table 1.

Characteristics of patients with AKI (n = 310).

Demographic Profiles and Comorbidities
Age (years), median (IQR) 69 (58–79)
Female, n (%) 125 (40.32)
BMI (kg/m2), median (IQR) 24.73 (21.30–28.73)
Baseline SCr (μmol/L), median (IQR) 83.10 (60.11–127.30)
Baseline eGFR (mL/min/1.73 m2), median (IQR) 71.65 (41.76–105.43)
Diabetes, n (%) 135 (43.55)
Hypertension, n (%) 163 (52.58)
Dyslipidemia, n (%) 47 (15.16)
CKD, n (%) 129 (41.61)
Heart Failure, n (%) 54 (17.42)
Vascular Disease, n (%) 78 (25.16)
Liver Disease, n (%) 93 (30.00)
Pulmonary Disease, n (%) 36 (11.61)
Malignancy, n (%) 142 (45.81)
Main Causes of AKI
Sepsis, n (%) 188 (60.65)
Cardiorenal Syndrome, n (%) 22 (7.10)
Hypovolemia, n (%) 13 (4.19)
Obstructive Uropathy, n (%) 13 (4.19)
Intrarenal Causes, n (%) 74 (23.87)
Hematologic and Biochemical Profiles at Diagnosis of AKI
SCr (µmol/L) at AKI Diagnosis, median (IQR) 228.96 (151.16–375.70)
eGFR (mL/min/1.73 m2) at AKI Diagnosis, median (IQR) 22.53 (12.06–35.38)
Hemoglobin (g/L), median (IQR) 100.00 (88.00–117.00)
Platelet (109/L), median (IQR) 169.50 (101.25–253.75)
BUN (mmol/L), median (IQR) 19.99 (12.50–29.27)
K (mmol/L), median (IQR) 4.20 (3.60–4.90)
Albumin (g/L), median (IQR) 29.00 (25.00–33.90)
Lactate (mmol/L), median (IQR) 1.84 (1.29–3.46)
pH, median (IQR) 7.39 (7.30–7.45)
HCO3 (mmol/L), median (IQR) 21.05 (17.10–25.38)
Bil-T (µmol/L), median (IQR) 17.10 (10.26–51.31)
RRT Status and 30-Day Mortality after AKI
RRT within 0–6 Days After AKI, n (%) 40 (12.90)
RRT within 7–14 Days After AKI, n (%) 38 (12.26)
30-Day Mortality After AKI, n (%) 71 (22.90)

AKI, acute kidney injury; BMI, body mass index; Bil-T, total bilirubin; BUN, blood urea nitrogen; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HCO3, blood bicarbonate; IQR, interquartile range; K, serum potassium; n, number; RRT, renal replacement therapy; SCr, serum creatinine.